JP2005507400A5 - - Google Patents

Download PDF

Info

Publication number
JP2005507400A5
JP2005507400A5 JP2003537607A JP2003537607A JP2005507400A5 JP 2005507400 A5 JP2005507400 A5 JP 2005507400A5 JP 2003537607 A JP2003537607 A JP 2003537607A JP 2003537607 A JP2003537607 A JP 2003537607A JP 2005507400 A5 JP2005507400 A5 JP 2005507400A5
Authority
JP
Japan
Prior art keywords
composition
dosage form
gabapentin
composition according
stomach
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2003537607A
Other languages
English (en)
Japanese (ja)
Other versions
JP5421511B2 (ja
JP2005507400A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/IB2002/005440 external-priority patent/WO2003035040A1/en
Publication of JP2005507400A publication Critical patent/JP2005507400A/ja
Publication of JP2005507400A5 publication Critical patent/JP2005507400A5/ja
Application granted granted Critical
Publication of JP5421511B2 publication Critical patent/JP5421511B2/ja
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

JP2003537607A 2001-10-25 2002-10-25 胃に留まるガバペンチン投薬を使用する処置方法 Expired - Fee Related JP5421511B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US33524801P 2001-10-25 2001-10-25
US60/335,248 2001-10-25
PCT/IB2002/005440 WO2003035040A1 (en) 2001-10-25 2002-10-25 Methods of treatment using a gastric retained gabapentin dosage

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2010179064A Division JP2010254713A (ja) 2001-10-25 2010-08-09 胃に留まるガバペンチン投薬を使用する処置方法

Publications (3)

Publication Number Publication Date
JP2005507400A JP2005507400A (ja) 2005-03-17
JP2005507400A5 true JP2005507400A5 (OSRAM) 2006-01-05
JP5421511B2 JP5421511B2 (ja) 2014-02-19

Family

ID=23310919

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2003537607A Expired - Fee Related JP5421511B2 (ja) 2001-10-25 2002-10-25 胃に留まるガバペンチン投薬を使用する処置方法
JP2010179064A Pending JP2010254713A (ja) 2001-10-25 2010-08-09 胃に留まるガバペンチン投薬を使用する処置方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2010179064A Pending JP2010254713A (ja) 2001-10-25 2010-08-09 胃に留まるガバペンチン投薬を使用する処置方法

Country Status (9)

Country Link
US (10) US7438927B2 (OSRAM)
EP (2) EP1439825B2 (OSRAM)
JP (2) JP5421511B2 (OSRAM)
AU (1) AU2002348828B2 (OSRAM)
CA (1) CA2464322C (OSRAM)
DK (1) DK1439825T4 (OSRAM)
MX (1) MXPA04003946A (OSRAM)
TW (1) TWI312285B (OSRAM)
WO (1) WO2003035040A1 (OSRAM)

Families Citing this family (154)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7056531B1 (en) * 2000-05-04 2006-06-06 Nature's Way Products, Inc. Sustained release compositions for orally administered substances and methods
JP4216713B2 (ja) 2001-06-11 2009-01-28 ゼノポート，インコーポレイティド Ｇａｂａ類似体のプロドラッグ、組成物およびその使用
US8048917B2 (en) 2005-04-06 2011-11-01 Xenoport, Inc. Prodrugs of GABA analogs, compositions and uses thereof
US20070184104A1 (en) * 2001-10-25 2007-08-09 Depomed, Inc. Gastric retentive gabapentin dosage forms and methods for using same
US20030152622A1 (en) * 2001-10-25 2003-08-14 Jenny Louie-Helm Formulation of an erodible, gastric retentive oral diuretic
US20060159743A1 (en) * 2001-10-25 2006-07-20 Depomed, Inc. Methods of treating non-nociceptive pain states with gastric retentive gabapentin
US7612112B2 (en) * 2001-10-25 2009-11-03 Depomed, Inc. Methods of treatment using a gastric retained gabapentin dosage
TWI312285B (en) 2001-10-25 2009-07-21 Depomed Inc Methods of treatment using a gastric retained gabapentin dosage
US20030091630A1 (en) * 2001-10-25 2003-05-15 Jenny Louie-Helm Formulation of an erodible, gastric retentive oral dosage form using in vitro disintegration test data
US7939102B2 (en) * 2002-06-07 2011-05-10 Torrent Pharmaceuticals Ltd. Controlled release formulation of lamotrigine
CN1668284A (zh) * 2002-06-07 2005-09-14 兰贝克赛实验室有限公司 加巴喷丁的缓释口服剂型
US7776314B2 (en) 2002-06-17 2010-08-17 Grunenthal Gmbh Abuse-proofed dosage system
NZ541008A (en) 2003-01-13 2007-09-28 Dynogen Pharmaceuticals Inc Method of treating functional bowel disorders
CN1832735A (zh) * 2003-07-29 2006-09-13 兰贝克赛实验室有限公司 与食物并行摄取加巴喷丁的新型给药方案及提高的口服生物有效度
US8075872B2 (en) 2003-08-06 2011-12-13 Gruenenthal Gmbh Abuse-proofed dosage form
DE102005005446A1 (de) 2005-02-04 2006-08-10 Grünenthal GmbH Bruchfeste Darreichungsformen mit retardierter Freisetzung
ES2407143T3 (es) * 2003-08-06 2013-06-11 Grünenthal GmbH Forma de dosificación protegida contra un posible abuso
DE102004020220A1 (de) * 2004-04-22 2005-11-10 Grünenthal GmbH Verfahren zur Herstellung einer gegen Missbrauch gesicherten, festen Darreichungsform
DE10361596A1 (de) * 2003-12-24 2005-09-29 Grünenthal GmbH Verfahren zur Herstellung einer gegen Missbrauch gesicherten Darreichungsform
DE102004032051A1 (de) * 2004-07-01 2006-01-19 Grünenthal GmbH Verfahren zur Herstellung einer gegen Missbrauch gesicherten, festen Darreichungsform
US20070048228A1 (en) * 2003-08-06 2007-03-01 Elisabeth Arkenau-Maric Abuse-proofed dosage form
DE10336400A1 (de) 2003-08-06 2005-03-24 Grünenthal GmbH Gegen Missbrauch gesicherte Darreichungsform
US20070191815A1 (en) 2004-09-13 2007-08-16 Chrono Therapeutics, Inc. Biosynchronous transdermal drug delivery
ITMI20032399A1 (it) * 2003-12-09 2005-06-10 Zambon Spa Composizione farmaceutica contenente gabapentina.
CN1921839A (zh) * 2004-01-19 2007-02-28 兰贝克赛实验室有限公司 加巴喷丁的稳定缓释口服剂型及其制备方法
GB0405200D0 (en) * 2004-03-08 2004-04-21 Pfizer Ltd Combinations comprising alpha-2-delta ligands
GB0408308D0 (en) * 2004-04-14 2004-05-19 Vectura Ltd Pharmaceutical compositions
US7427601B2 (en) * 2004-06-24 2008-09-23 Schwarz Pharma Ag Method for treating tremor
DE102004032049A1 (de) 2004-07-01 2006-01-19 Grünenthal GmbH Gegen Missbrauch gesicherte, orale Darreichungsform
WO2006027681A1 (en) * 2004-09-07 2006-03-16 Pfizer Limited Combination of a 5-ht(1) receptor agonist and an alpha-2-delta ligand for the treatment of migraine
US8252321B2 (en) 2004-09-13 2012-08-28 Chrono Therapeutics, Inc. Biosynchronous transdermal drug delivery for longevity, anti-aging, fatigue management, obesity, weight loss, weight management, delivery of nutraceuticals, and the treatment of hyperglycemia, alzheimer's disease, sleep disorders, parkinson's disease, aids, epilepsy, attention deficit disorder, nicotine addiction, cancer, headache and pain control, asthma, angina, hypertension, depression, cold, flu and the like
NZ554737A (en) 2004-11-04 2011-04-29 Xenoport Inc Gabapentin prodrug sustained release oral dosage forms
DE102005005449A1 (de) * 2005-02-04 2006-08-10 Grünenthal GmbH Verfahren zur Herstellung einer gegen Missbrauch gesicherten Darreichungsform
WO2006113568A2 (en) * 2005-04-19 2006-10-26 Alza Corporation Controlled delivery dosage form of tramadol and gabapentin
DK1919466T3 (da) 2005-07-11 2012-07-02 Cortria Corp Formuleringer til behandling af lipoprotein-abnormiteter omfattende et statin og et methylnicotinamidderivat
US20070092565A1 (en) * 2005-10-25 2007-04-26 Pharmascience Inc. Gastric retention drug delivery system
NL2000281C2 (nl) 2005-11-02 2007-08-07 Pfizer Prod Inc Vaste farmaceutische samenstellingen die pregabaline bevatten.
US20090176882A1 (en) * 2008-12-09 2009-07-09 Depomed, Inc. Gastric retentive gabapentin dosage forms and methods for using same
CA2635466A1 (en) * 2005-12-29 2007-07-12 Depomed, Inc. Gastric retentive gabapentin dosage forms and methods for using same
DE102007011485A1 (de) * 2007-03-07 2008-09-11 Grünenthal GmbH Darreichungsform mit erschwertem Missbrauch
WO2008118369A2 (en) 2007-03-22 2008-10-02 Dendreon Corporation Methods for inducing a natural killer (nk) cell-mediated immune response and for increasing nk cell activity
JP5774853B2 (ja) 2008-01-25 2015-09-09 グリュネンタール・ゲゼルシャフト・ミト・ベシュレンクテル・ハフツング 医薬投薬形
WO2009102734A1 (en) * 2008-02-11 2009-08-20 Depomed Inc. Methods for treating vasomotor symptoms using gaba analogs in a gastric retentive dosage form
CN102105136B (zh) 2008-03-11 2014-11-26 蒂宝制药公司 包含非-阿片类止痛剂和阿片类止痛剂的组合的胃滞留型缓释剂型
US8372432B2 (en) 2008-03-11 2013-02-12 Depomed, Inc. Gastric retentive extended-release dosage forms comprising combinations of a non-opioid analgesic and an opioid analgesic
SG176464A1 (en) 2008-05-09 2011-12-29 Agency Science Tech & Res Diagnosis and treatment of kawasaki disease
WO2009135680A1 (en) * 2008-05-09 2009-11-12 Grünenthal GmbH Process for the preparation of an intermediate powder formulation and a final solid dosage form under usage of a spray congealing step
AU2009281752B2 (en) * 2008-08-15 2016-11-17 Depomed Inc. Gastric retentive pharmaceutical compositions for treatment and prevention of CNS disorders
CA3031836A1 (en) 2009-05-05 2010-11-11 Board Of Regents, The University Of Texas System Formulations of volatile anesthetics for reducing inflammation
PL2997965T3 (pl) * 2009-07-22 2019-06-28 Grünenthal GmbH Odporna na manipulacje postać dawkowania opioidów wrażliwych na utlenianie
WO2011009602A1 (en) 2009-07-22 2011-01-27 Grünenthal GmbH Hot-melt extruded controlled release dosage form
WO2011034920A1 (en) * 2009-09-16 2011-03-24 Allergan, Inc. Compositions and methods for treating seizure disorders
US20110135728A1 (en) * 2009-12-08 2011-06-09 Miller Jennifer L Gastric retentive pharmaceutical compositions for extended release of polypeptides
US9198861B2 (en) 2009-12-22 2015-12-01 Mallinckrodt Llc Methods of producing stabilized solid dosage pharmaceutical compositions containing morphinans
US8597681B2 (en) 2009-12-22 2013-12-03 Mallinckrodt Llc Methods of producing stabilized solid dosage pharmaceutical compositions containing morphinans
CA2832436C (en) * 2010-04-07 2018-08-14 Lupin Limited Controlled release pharmaceutical compositions of tapentadol
US20130078290A1 (en) * 2010-06-01 2013-03-28 Rubicon Research Private Limited Gastroretentive Dosage Forms Of GABA Analogs
JP6005636B2 (ja) * 2010-07-06 2016-10-12 グリュネンタール・ゲゼルシャフト・ミト・ベシュレンクテル・ハフツング Ｇａｂａ類似体及びオピオイドを含む新規胃内滞留型剤形
CA2807661C (en) 2010-08-11 2019-09-10 Philadelphia Health & Education Corporation D/B/A Drexel University College Of Medicine Novel d3 dopamine receptor agonists to treat dyskinesia in parkinson's disease
EP2611426B1 (en) 2010-09-02 2014-06-25 Grünenthal GmbH Tamper resistant dosage form comprising inorganic salt
ES2487244T3 (es) 2010-09-02 2014-08-20 Grünenthal GmbH Forma de dosificación resistente a la manipulación que comprende un polímero aniónico
EP2648754A4 (en) 2010-12-07 2016-02-24 Philadelphia Health & Educatio METHOD OF INHIBITING CANCER METASTASES
US8476221B2 (en) 2011-03-18 2013-07-02 Halimed Pharmaceuticals, Inc. Methods and compositions for the treatment of metabolic disorders
US8741885B1 (en) 2011-05-17 2014-06-03 Mallinckrodt Llc Gastric retentive extended release pharmaceutical compositions
US9050335B1 (en) 2011-05-17 2015-06-09 Mallinckrodt Llc Pharmaceutical compositions for extended release of oxycodone and acetaminophen resulting in a quick onset and prolonged period of analgesia
US8858963B1 (en) 2011-05-17 2014-10-14 Mallinckrodt Llc Tamper resistant composition comprising hydrocodone and acetaminophen for rapid onset and extended duration of analgesia
CA2841785A1 (en) 2011-07-06 2013-01-10 The Parkinson's Institute Compositions and methods for treatment of symptoms in parkinson's disease patients
CA2839123A1 (en) 2011-07-29 2013-02-07 Grunenthal Gmbh Tamper-resistant tablet providing immediate drug release
US20130028972A1 (en) 2011-07-29 2013-01-31 Grunenthal Gmbh Tamper-resistant tablet providing immediate drug release
US20130143867A1 (en) 2011-12-02 2013-06-06 Sychroneuron Inc. Acamprosate formulations, methods of using the same, and combinations comprising the same
SG11201402660YA (en) 2011-12-21 2014-10-30 Novira Therapeutics Inc Hepatitis b antiviral agents
JP6117249B2 (ja) 2012-02-28 2017-04-19 グリュネンタール・ゲゼルシャフト・ミト・ベシュレンクテル・ハフツング 薬理学的に活性な化合物および陰イオン性ポリマーを含むタンパーレジスタント剤形
HRP20181716T1 (hr) 2012-04-18 2018-12-28 Grünenthal GmbH Farmaceutski oblik doziranja otporan na zlonamjernu uporabu i naglo oslobađanje cjelokupne doze
US10064945B2 (en) 2012-05-11 2018-09-04 Gruenenthal Gmbh Thermoformed, tamper-resistant pharmaceutical dosage form containing zinc
CA2879454A1 (en) 2012-07-19 2014-01-23 Drexel University Novel sigma receptor ligands and methods of modulating cellular protein homeostasis using same
CN104768544B (zh) 2012-08-09 2017-06-16 迪纳米斯治疗公司 包括葡甲胺或其盐的组合物在制备减少或预防甘油三酯水平增加的药物中的应用
EP2698144A1 (en) 2012-08-12 2014-02-19 Ali Raif Ilaç Sanayi ve Ticaret Anonim Sirketi Prolonged release gabapentin tablet formulation whose ability to stay in the stomach is improved
CN105025854A (zh) 2013-01-07 2015-11-04 宾夕法尼亚大学董事会 治疗皮肤t细胞淋巴瘤的组合物和方法
WO2014191397A1 (en) 2013-05-29 2014-12-04 Grünenthal GmbH Tamper-resistant dosage form containing one or more particles
US9737490B2 (en) 2013-05-29 2017-08-22 Grünenthal GmbH Tamper resistant dosage form with bimodal release profile
EP3878445A3 (en) 2013-06-05 2021-10-27 Synchroneuron Inc. Acamprosate formulations, methods of using the same, and combinations comprising the same
EP3613861A1 (en) 2013-07-02 2020-02-26 EcoPlanet Environmental LLC Volatile organic compound formulations having antimicrobial activity
GB201311888D0 (en) 2013-07-03 2013-08-14 Glaxosmithkline Ip Dev Ltd Novel compounds
GB201311891D0 (en) 2013-07-03 2013-08-14 Glaxosmithkline Ip Dev Ltd Novel compound
WO2015004245A1 (en) 2013-07-12 2015-01-15 Grünenthal GmbH Tamper-resistant dosage form containing ethylene-vinyl acetate polymer
US9908915B2 (en) 2013-11-26 2018-03-06 Yale University Cell-penetrating compositions and methods using same
HK1224189A1 (zh) 2013-11-26 2017-08-18 Grünenthal GmbH 通过低温研磨制备粉状药物组合物
CA2933464A1 (en) 2013-12-09 2015-06-18 Thomas Jefferson University Use of abc drug efflux inhibitors in combination with anti-neurodegenerative drugs in the treatment of neurodegenerative disorders
CA2982270C (en) 2014-04-07 2023-01-10 Women & Infants Hospital Of Rhode Island Novel 7-dehydrocholesterol derivatives and methods using same
US20180228907A1 (en) 2014-04-14 2018-08-16 Arvinas, Inc. Cereblon ligands and bifunctional compounds comprising the same
MX2016014738A (es) 2014-05-12 2017-03-06 Gruenenthal Gmbh Formulacion en capsula de liberacion inmediata resistente a alteraciones que comprende tapentadol.
MX2016015417A (es) 2014-05-26 2017-02-22 Gruenenthal Gmbh Multiparticulas protegidas contra vertido de dosis etanolico.
CA2968215A1 (en) 2014-08-20 2016-02-25 Yale University Novel compositions and methods useful for treating or preventing liver diseases or disorders, and promoting weight loss
JP2018511355A (ja) 2015-01-28 2018-04-26 クロノ セラピューティクス インコーポレイテッドＣｈｒｏｎｏ Ｔｈｅｒａｐｅｕｔｉｃｓ Ｉｎｃ． 薬剤送達方法及びシステム
AU2016228779A1 (en) 2015-03-12 2017-09-07 Chrono Therapeutics Inc. Craving input and support system
EA035434B1 (ru) 2015-04-24 2020-06-15 Грюненталь Гмбх Защищенная от применения не по назначению лекарственная форма с немедленным высвобождением и устойчивостью к экстракции растворителями
WO2016182968A1 (en) 2015-05-08 2016-11-17 Brown University Novel syringolin analogues and methods of making and using same
EP3298140B1 (en) 2015-05-19 2024-04-24 Yale University Compositions for treating pathological calcification conditions, and methods using same
US10829440B2 (en) 2015-06-12 2020-11-10 Brown University Antibacterial compounds and methods of making and using same
JP6731427B2 (ja) 2015-06-30 2020-07-29 ネウラッド リミテッドＮｅｕｒａｄ Ｌｔｄ． 新規の呼吸制御調節化合物、およびこれを製造し、かつ使用する方法
EP3346991A1 (en) 2015-09-10 2018-07-18 Grünenthal GmbH Protecting oral overdose with abuse deterrent immediate release formulations
JP6970667B2 (ja) 2015-10-28 2021-11-24 イエール ユニバーシティ キノリンアミドおよびその使用法
US20180371434A1 (en) 2015-11-20 2018-12-27 Yale University Compositions for Treating Ectopic Calcification Disorders, and Methods Using Same
US10292977B2 (en) 2016-04-11 2019-05-21 Neurocea, LLC Compositions and methods for treatment related to fall and fall frequency in neurodegenerative diseases
US10143687B2 (en) 2016-04-11 2018-12-04 Neurocea, LLC Compositions and methods for treatment related to fall and fall frequency in neurodegenerative diseases
US20190119364A1 (en) 2016-04-29 2019-04-25 The Regents Of The University Of Colorado, A Body Corporate Compounds and compositions useful for treating metabolic syndrome, and methods using same
WO2018015946A1 (en) 2016-07-17 2018-01-25 Mapi Pharma Ltd. Extended release dosage forms of pregabalin
WO2018026764A1 (en) 2016-08-01 2018-02-08 University Of Rochester Nanoparticles for controlled release of anti-biofilm agents and methods of use
AU2017306549A1 (en) 2016-08-05 2019-02-21 Yale University Compositions and methods for stroke prevention in pediatric sickle cell anemia patients
US10683283B2 (en) 2016-09-01 2020-06-16 Mebias Discovery, Inc. Substituted ureas and methods of making and using same
JP7113009B2 (ja) 2016-11-07 2022-08-04 アービュタス バイオファーマ コーポレイション 置換ピリジノン含有三環式化合物およびそれを使用する方法
JP2020503950A (ja) 2017-01-06 2020-02-06 クロノ セラピューティクス インコーポレイテッドＣｈｒｏｎｏ Ｔｈｅｒａｐｅｕｔｉｃｓ Ｉｎｃ． 経皮薬剤送達の装置及び方法
US10941126B2 (en) 2017-01-19 2021-03-09 Temple University-Of The Commonwealth System Of Higher Education Bridged bicycloalkyl-substituted aminothiazoles and their methods of use
US11098010B2 (en) 2017-03-21 2021-08-24 Arbutus Biopharma Corporation Substituted dihydroindene-4-carboxamides and analogs thereof, and methods using same
CN110753546B (zh) 2017-04-17 2023-11-10 耶鲁大学 治疗或预防急性肺损伤的化合物、组合物和方法
WO2019023621A1 (en) 2017-07-28 2019-01-31 Yale University ANTICANCER DRUGS AND METHODS OF MAKING AND USING THEM
AU2018330171A1 (en) 2017-09-08 2020-03-12 The Regents Of The University Of Colorado, A Body Corporate Compounds, compositions and methods for treating or preventing HER-driven drug-resistant cancers
CN111818929A (zh) 2017-11-27 2020-10-23 由卫生与公众服务部部长代表的美利坚合众国 用于治疗和/或预防牙周疾病的化合物、组合物和方法
WO2019125184A1 (en) 2017-12-19 2019-06-27 Auckland Uniservices Limited Use of biomarker in cancer therapy
WO2019240740A1 (en) 2017-12-22 2019-12-19 Arasteh Ari Azhir Compositions and methods for treatment related to fall and fall frequency in neurodegenerative diseases
SG11202006994XA (en) 2018-01-24 2020-08-28 Univ Rockefeller Antibacterial compounds, compositions thereof, and methods using same
AU2019211458B2 (en) 2018-01-29 2024-08-29 Duke University Compositions and methods of enhancing 5-hydroxytryptophan bioavailability
CA3101680A1 (en) 2018-05-25 2019-11-28 Temple University-Of The Commonwealth System Of Higher Education Eradication of bacterial biofilm using anti-amyloid monoclonal antibodies
EA202092691A1 (ru) 2018-05-29 2021-04-21 Церси Терапьютикс, Инк. Соединения для устранения боли, композиции, содержащие их, и способы их применения
JP7420797B2 (ja) 2018-05-29 2024-01-23 モーニングサイド ベンチャー インベストメンツ リミテッド 薬剤送達の方法及びシステム
KR20210031910A (ko) 2018-06-19 2021-03-23 싱가포르국립대학교 다양한 적응증에 대한 향상된 생체 이용률을 위한 5-하이드록시트립토판의 제형
TWI826492B (zh) 2018-07-27 2023-12-21 加拿大商愛彼特生物製藥公司 經取代四氫環戊[c]吡咯、經取代二氫吡咯，其類似物及使用其之方法
WO2020037146A1 (en) 2018-08-17 2020-02-20 The Trustees Of The University Of Pennsylvania Compositions and methods for treatment of acute lung injury
WO2020074944A1 (en) 2018-10-11 2020-04-16 Sanifit Therapeutics S.A. Inositol phosphates for the treatment of ectopic calcification
WO2020081762A1 (en) 2018-10-19 2020-04-23 Temple University-Of The Commonwealth System Of Higher Education Tamper-resistant drug dosage forms and methods of making and use thereof
CA3119992A1 (en) 2018-11-16 2020-05-22 Morningside Venture Investments Limited Thermally regulated transdermal drug delivery system
TWI827760B (zh) 2018-12-12 2024-01-01 加拿大商愛彼特生物製藥公司 經取代之芳基甲基脲類及雜芳基甲基脲類、其類似物及其使用方法
EP3917535A1 (en) 2019-01-30 2021-12-08 Sanifit Therapeutics S.A. Inositol phosphate compounds for use in increasing tissular perfusion
US20200246317A1 (en) 2019-02-01 2020-08-06 Cersci Therapeutics, Inc. Methods of treating diabetic neuropathy with a thiazoline anti-hyperalgesic agent
US20200246316A1 (en) 2019-02-01 2020-08-06 Cersci Therapeutics, Inc. Methods of treating post-surgical pain with a thiazoline anti-hyperalgesic agent
US11524048B2 (en) 2019-05-09 2022-12-13 The Feinstein Institutes For Medical Research HMGB1 antagonist treatment of severe sepsis
CA3143196A1 (en) 2019-06-12 2020-12-17 The Wistar Institute Acetyl-coa synthetase 2 (acss2) inhibitors and methods using same
US11555010B2 (en) 2019-07-25 2023-01-17 Brown University Diamide antimicrobial agents
EP3818983A1 (en) 2019-11-11 2021-05-12 Sanifit Therapeutics S.A. Inositol phosphate compounds for use in treating, inhibiting the progression, or preventing cardiovascular calcification
WO2021127456A1 (en) 2019-12-19 2021-06-24 Rain Therapeutics Inc. Methods of inhibiting epidermal growth factor receptor proteins
BR112022024958A2 (pt) 2020-06-09 2022-12-27 Inozyme Pharma Inc Proteínas enpp1 solúveis e usos das mesmas
EP4015494A1 (en) 2020-12-15 2022-06-22 Sanifit Therapeutics S.A. Processes for the preparation of soluble salts of inositol phosphates
EP4036097A1 (en) 2021-01-29 2022-08-03 Sanifit Therapeutics S.A. Ip4-4,6 substituted derivative compounds
EP4362919A1 (en) 2021-07-30 2024-05-08 Evecxia Therapeutics, Inc. 5-hydroxytryptophan gastroretentive dosage forms
US12409163B2 (en) 2021-07-30 2025-09-09 Evecxia Therapeutics, Inc. Method of enhancing 5-hydroxytryptophan (5-HTP) exposure
JP2024535585A (ja) 2021-10-14 2024-09-30 エヴェクシア セラピューティクス， インク． 脳内５－ヒドロキシトリプタミンの機能を治療目的で最適化する方法
CN119855595A (zh) 2022-07-29 2025-04-18 萨尼菲特治疗有限公司 用于治疗异位钙化、抑制进展和预防异位钙化的ip4-4,6取代的衍生物化合物
TW202412815A (zh) 2022-07-29 2024-04-01 西班牙商薩尼菲特治療公司 Ip5經取代化合物
WO2024052895A1 (en) 2022-09-06 2024-03-14 Hadasit Medical Research Services And Development Ltd Combinations comprising psychedelics for the treatment of schizophrenia and other neuropsychiatric and neurologic disorders
US20250057848A1 (en) 2023-08-14 2025-02-20 Neurim Pharmaceuticals (1991) Ltd. Gal475 compositions and methods of use thereof
WO2025162971A1 (en) 2024-01-31 2025-08-07 Sanifit Therapeutics, S.A. Substituted ip5 compounds for use in the treatment, inhibition of progression, and prevention of ectopic calcification
WO2025217094A1 (en) 2024-04-08 2025-10-16 University Of Rochester Interleukin receptor-associated kinase (irak) protac degraders and medical use thereof
WO2025217096A1 (en) 2024-04-08 2025-10-16 University Of Rochester Inhibitors of leucine-rich repeat kinase 2 (lrrk2) and medical uses thereof
WO2025217379A1 (en) 2024-04-10 2025-10-16 University Of Rochester Drug treatment for macular degeneration

Family Cites Families (122)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US43946A (en) * 1864-08-23 Improvement in hay-elevating forks
US12679A (en) * 1855-04-10 phdto-litho
US3574820A (en) 1968-01-08 1971-04-13 Upjohn Co Medicinal dosage forms of unpolymerized thiolated gelatin with a cross-linking accelerating agent providing slowly released medication from a swollen matrix
US3845770A (en) * 1972-06-05 1974-11-05 Alza Corp Osmatic dispensing device for releasing beneficial agent
US4087544A (en) * 1974-12-21 1978-05-02 Warner-Lambert Company Treatment of cranial dysfunctions using novel cyclic amino acids
DE2460891C2 (de) * 1974-12-21 1982-09-23 Gödecke AG, 1000 Berlin 1-Aminomethyl-1-cycloalkanessigsäuren und deren Ester, Verfahren zu deren Herstellung und diese Verbindungen enthaltende Arzneimittel
US3977404A (en) * 1975-09-08 1976-08-31 Alza Corporation Osmotic device having microporous reservoir
DE2611690A1 (de) * 1976-03-19 1977-09-22 Goedecke Ag Cyclische sulfonyloxyimide
CA1146866A (en) 1979-07-05 1983-05-24 Yamanouchi Pharmaceutical Co. Ltd. Process for the production of sustained release pharmaceutical composition of solid medical material
US4309406A (en) * 1979-07-10 1982-01-05 American Home Products Corporation Sustained release pharmaceutical compositions
US4612008A (en) * 1983-05-11 1986-09-16 Alza Corporation Osmotic device with dual thermodynamic activity
US4462839A (en) * 1983-06-16 1984-07-31 Fmc Corporation Enteric coating for pharmaceutical dosage forms
US4753801A (en) * 1985-10-25 1988-06-28 Eli Lilly And Company Sustained release tablets
GB8613689D0 (en) 1986-06-05 1986-07-09 Euro Celtique Sa Pharmaceutical composition
US4851232A (en) 1987-02-13 1989-07-25 Alza Corporation Drug delivery system with means for obtaining desirable in vivo release rate pattern
US4786503A (en) * 1987-04-06 1988-11-22 Alza Corporation Dosage form comprising parallel lamine
IL87710A (en) 1987-09-18 1992-06-21 Ciba Geigy Ag Covered floating retard form for controlled release in gastric juice
US4894476A (en) * 1988-05-02 1990-01-16 Warner-Lambert Company Gabapentin monohydrate and a process for producing the same
US5002772A (en) 1988-05-31 1991-03-26 Pfizer Inc. Gastric retention system for controlled drug release
US5007790A (en) * 1989-04-11 1991-04-16 Depomed Systems, Inc. Sustained-release oral drug dosage form
DE3928183A1 (de) * 1989-08-25 1991-02-28 Goedecke Ag Lactamfreie cyclische aminosaeuren
US5084479A (en) * 1990-01-02 1992-01-28 Warner-Lambert Company Novel methods for treating neurodegenerative diseases
EP0458751A1 (en) 1990-05-25 1991-11-27 Warner-Lambert Company Delivery system for cyclic amino acids with improved taste, texture and compressibility
IT1250483B (it) 1990-08-30 1995-04-07 Eurand Int Sistema di ritardo a matrice multipla
US5827819A (en) * 1990-11-01 1998-10-27 Oregon Health Sciences University Covalent polar lipid conjugates with neurologically active compounds for targeting
US5232704A (en) 1990-12-19 1993-08-03 G. D. Searle & Co. Sustained release, bilayer buoyant dosage form
US5273758A (en) 1991-03-18 1993-12-28 Sandoz Ltd. Directly compressible polyethylene oxide vehicle for preparing therapeutic dosage forms
EP0632720B1 (en) 1992-03-25 1998-11-11 Depomed Systems, Inc. Hydroxyethylcellulose-based sustained-release oral drug dosage froms
US5582837A (en) * 1992-03-25 1996-12-10 Depomed, Inc. Alkyl-substituted cellulose-based sustained-release oral drug dosage forms
US5382435A (en) * 1993-03-24 1995-01-17 Southwest Research Institute Microparticulate pharmaceutical delivery system
NZ260408A (en) 1993-05-10 1996-05-28 Euro Celtique Sa Controlled release preparation comprising tramadol
US5500227A (en) * 1993-11-23 1996-03-19 Euro-Celtique, S.A. Immediate release tablet cores of insoluble drugs having sustained-release coating
DE4406424A1 (de) 1994-02-28 1995-08-31 Bayer Ag Expandierbare Arzneiformen
ZA953078B (en) 1994-04-28 1996-01-05 Alza Corp Effective therapy for epilepsies
AU684361B2 (en) 1994-04-29 1997-12-11 Mcneil-Ppc, Inc. Layered absorbent products
EP0758244B2 (en) 1994-05-06 2008-02-13 Pfizer Inc. Controlled-release dosage forms of azithromycin
DE4432757A1 (de) 1994-09-14 1996-03-21 Boehringer Mannheim Gmbh Pharmazeutische Zubereitung enthaltend Metformin und Verfahren zu deren Herstellung
MY113429A (en) 1995-02-28 2002-02-28 Univ Temple Controlled release tablet containing swellable polyethylene oxide
US5945125A (en) 1995-02-28 1999-08-31 Temple University Controlled release tablet
ATE214596T1 (de) 1995-04-14 2002-04-15 Pharma Pass Feste zusammensetzungen mit einem nicht-amorphem wirkstoff und polyäthylenoxyd
US6117453A (en) 1995-04-14 2000-09-12 Pharma Pass Solid compositions containing polyethylene oxide and an active ingredient
US5558879A (en) 1995-04-28 1996-09-24 Andrx Pharmaceuticals, Inc. Controlled release formulation for water soluble drugs in which a passageway is formed in situ
GB9523752D0 (en) 1995-11-21 1996-01-24 Pfizer Ltd Pharmaceutical formulations
US5783212A (en) * 1996-02-02 1998-07-21 Temple University--of the Commonwealth System of Higher Education Controlled release drug delivery system
AU3290397A (en) 1996-06-10 1998-01-07 Depomed, Inc. Gastric-retentive oral controlled drug delivery system with enhanced retention properties
ATE293458T1 (de) * 1996-08-23 2005-05-15 Algos Pharm Corp Antikonvulsive mitteln enthaltende zubereitung zur behandlung von neuropathischen schmerzen
US5972389A (en) 1996-09-19 1999-10-26 Depomed, Inc. Gastric-retentive, oral drug dosage forms for the controlled-release of sparingly soluble drugs and insoluble matter
US6255526B1 (en) * 1996-12-24 2001-07-03 Teva Pharmaceutical Industries Ltd. Preparation of gabapentin
US5872984A (en) * 1997-04-01 1999-02-16 International Business Machines Corporation Uninterruptible power supply providing continuous power mainstore function for a computer system
US20010046473A1 (en) * 1997-04-18 2001-11-29 Jerome Besse Gastric-retained pharmaceutical composition and method for its use
EP0998271B3 (en) * 1997-06-06 2014-10-29 Depomed, Inc. Gastric-retentive oral drug dosage forms for controlled release of highly soluble drugs
US6635280B2 (en) 1997-06-06 2003-10-21 Depomed, Inc. Extending the duration of drug release within the stomach during the fed mode
US6432986B2 (en) * 1997-07-21 2002-08-13 Bruce H. Levin Compositions, kits, and methods for inhibiting cerebral neurovascular disorders and muscular headaches
US20010004644A1 (en) * 1997-07-21 2001-06-21 Levin Bruce H. Compositions, kits, apparatus, and methods for inhibiting cephalic inflammation
US6110499A (en) * 1997-07-24 2000-08-29 Alza Corporation Phenytoin therapy
WO1999007342A1 (en) † 1997-08-11 1999-02-18 Alza Corporation Prolonged release active agent dosage form adapted for gastric retention
WO1999008670A1 (en) * 1997-08-20 1999-02-25 Guglietta, Antonio Gaba analogs to prevent and treat gastrointestinal damage
WO1999012537A1 (en) * 1997-09-08 1999-03-18 Warner-Lambert Company Analgesic compositions comprising anti-epileptic compounds and methods of using same
FR2769107B1 (fr) * 1997-09-30 2001-07-13 Centre Nat Rech Scient Procede de codage, equipement pour le codage et produit ainsi code
WO1999018063A2 (en) * 1997-10-07 1999-04-15 Warner-Lambert Company Process for preparing a cyclic amino acid anticonvulsant compound
CA2220038A1 (en) 1998-01-05 1999-07-05 Amina Odidi Device for the delivery of high dose pharmaceutical, neutraceutical, agricultural, biological, and chemical substances
CN1203846C (zh) 1998-03-19 2005-06-01 布里斯托尔-迈尔斯斯奎布公司 高溶解性药物的双相控释递送系统和方法
US20040062802A1 (en) * 1998-04-02 2004-04-01 Hermelin Victor M. Maximizing effectiveness of substances used to improve health and well being
FR2781793B1 (fr) 1998-08-03 2001-07-20 Prographarm Lab Procede de fabrication de granules de gabapentine enrobes
DE29823446U1 (de) 1998-09-03 1999-06-17 Kraft, Stefan, 85669 Pastetten Scheuerschutzvorrichtung, insbesondere Kantenscheuerschutzvorrichtung
US6635281B2 (en) * 1998-12-23 2003-10-21 Alza Corporation Gastric retaining oral liquid dosage form
US7214711B2 (en) * 1998-12-23 2007-05-08 Neurotherapeutics Pharma Llc Method of treating migraine headache without aura
US6294192B1 (en) * 1999-02-26 2001-09-25 Lipocine, Inc. Triglyceride-free compositions and methods for improved delivery of hydrophobic therapeutic agents
CA2359485A1 (en) 1999-03-10 2000-09-14 Warner-Lambert Company Analgesic compositions comprising anti-epileptic compounds and methods of using same
KR20100036398A (ko) * 1999-03-31 2010-04-07 얀센 파마슈티카 엔.브이. 방출 조절형 제제중의 프리젤라틴화 전분
US6162466A (en) * 1999-04-15 2000-12-19 Taro Pharmaceutical Industries Ltd. Sustained release formulation of carbamazepine
US7919119B2 (en) * 1999-05-27 2011-04-05 Acusphere, Inc. Porous drug matrices and methods of manufacture thereof
HK1046244B (zh) * 1999-06-14 2005-06-03 科斯默技术有限公司 控制释放与掩蔽味道的口服药物组合物
CA2378918C (en) * 1999-07-22 2007-01-23 University Of Rochester Method of treating symptoms of hormonal variation, including hot flashes
US6294198B1 (en) 1999-08-24 2001-09-25 Purepac Pharmaceutical Co. Pharmaceutical tablet formulation containing gabapentin with improved physical and chemical characteristics and method of making the same
JP2004510687A (ja) * 1999-11-02 2004-04-08 ディポメド，インコーポレイティド 胃への薬剤投与の強化のための供給モードの薬理学的誘導
IL133196A0 (en) * 1999-11-29 2001-03-19 Yissum Res Dev Co Gastroretentive controlled release pharmaceutical dosage forms
EP1118321A1 (fr) * 2000-01-14 2001-07-25 Ucb, S.A. Compositions pharmaceutiques solides pour la libération contrôlée de substances actives
ATE340563T1 (de) 2000-02-04 2006-10-15 Depomed Inc DOSIERUNGSFORM DES TYPS ßHÜLLE UND KERNß MIT EINER WIRKSTOFFFREISETZUNG, DIE SICH DER NULLTEN ORDNUNG ANNÄHERT
US6333352B1 (en) * 2000-04-05 2001-12-25 Mimicking Man Manually, Inc. Method of treating benign positional vertigo
US20010036943A1 (en) * 2000-04-07 2001-11-01 Coe Jotham W. Pharmaceutical composition for treatment of acute, chronic pain and/or neuropathic pain and migraines
WO2001076478A1 (en) 2000-04-10 2001-10-18 Nordisk Terapi As System for testing and exercising sensorimotoric control of the neck
US6350471B1 (en) 2000-05-31 2002-02-26 Pharma Pass Llc Tablet comprising a delayed release coating
WO2001097782A1 (en) 2000-06-16 2001-12-27 Teva Pharmaceutical Industries, Ltd. Stable gabapentin having ph within a controlled range
DE1289364T1 (de) 2000-06-16 2003-09-18 Teva Pharmaceutical Industries Ltd., Petah Tiqva Stabiles gabapentin, das mehr als 20 ppm chlor enthält
US6488962B1 (en) * 2000-06-20 2002-12-03 Depomed, Inc. Tablet shapes to enhance gastric retention of swellable controlled-release oral dosage forms
US6451808B1 (en) * 2000-10-17 2002-09-17 Depomed, Inc. Inhibition of emetic effect of metformin with 5-HT3 receptor antagonists
US6683112B2 (en) 2000-10-24 2004-01-27 Andrx Corporation Gabapentin prodrugs and formulations
HK1054195B (zh) * 2001-02-27 2005-09-09 Evonik Röhm Gmbh 用於提高了儲存穩定性的藥物製劑的包衣及粘合劑
JP2004532259A (ja) * 2001-05-29 2004-10-21 デポメッド ディベロップメント リミティド 胃食道逆流症及び夜間に胃酸分泌が回復する現象の治療方法
US7420002B2 (en) * 2001-06-11 2008-09-02 Xenoport Amino acid conjugates providing for sustained systemic concentrations of GABA analogues
ITMI20011338A1 (it) 2001-06-26 2002-12-26 Farmatron Ltd Composizioni farmaceutiche orali a rilascio immediato del principio attivo
ITMI20011337A1 (it) * 2001-06-26 2002-12-26 Farmatron Ltd Composizioni farmaceutiche orali a rilascio modificato del principio attivo
MXPA03012041A (es) * 2001-07-04 2004-03-26 Sun Pharmaceutical Ind Ltd Sistema de administracion controlada de farmacos de retencion gastrica.
US20030104052A1 (en) * 2001-10-25 2003-06-05 Bret Berner Gastric retentive oral dosage form with restricted drug release in the lower gastrointestinal tract
US20070184104A1 (en) * 2001-10-25 2007-08-09 Depomed, Inc. Gastric retentive gabapentin dosage forms and methods for using same
US20030152622A1 (en) * 2001-10-25 2003-08-14 Jenny Louie-Helm Formulation of an erodible, gastric retentive oral diuretic
US7612112B2 (en) 2001-10-25 2009-11-03 Depomed, Inc. Methods of treatment using a gastric retained gabapentin dosage
US20030091630A1 (en) * 2001-10-25 2003-05-15 Jenny Louie-Helm Formulation of an erodible, gastric retentive oral dosage form using in vitro disintegration test data
TWI312285B (en) 2001-10-25 2009-07-21 Depomed Inc Methods of treatment using a gastric retained gabapentin dosage
US6723340B2 (en) * 2001-10-25 2004-04-20 Depomed, Inc. Optimal polymer mixtures for gastric retentive tablets
CA2409552A1 (en) * 2001-10-25 2003-04-25 Depomed, Inc. Gastric retentive oral dosage form with restricted drug release in the lower gastrointestinal tract
US20060159743A1 (en) * 2001-10-25 2006-07-20 Depomed, Inc. Methods of treating non-nociceptive pain states with gastric retentive gabapentin
CA2473536A1 (en) * 2002-01-16 2003-07-31 Endo Pharmaceuticals, Inc. Pharmaceutical composition and method for treating disorders of the central nervous system
US6682759B2 (en) 2002-02-01 2004-01-27 Depomed, Inc. Manufacture of oral dosage forms delivering both immediate-release and sustained-release drugs
US6559293B1 (en) * 2002-02-15 2003-05-06 Transform Pharmaceuticals, Inc. Topiramate sodium trihydrate
CN1668284A (zh) * 2002-06-07 2005-09-14 兰贝克赛实验室有限公司 加巴喷丁的缓释口服剂型
WO2004006841A2 (en) * 2002-07-12 2004-01-22 University Of Rochester Use of amino acids for treatment of various conditions
WO2004084880A1 (en) * 2003-03-21 2004-10-07 Dynogen Pharmaceuticals, Inc. METHODS FOR TREATING PAIN USING SMOOTH MUSCLE MODULATORS AND α2δ SUBUNIT CALCIUM CHANNEL MODULATORS
AU2005304352A1 (en) * 2004-11-10 2006-05-18 The Trustees Of Columbia University In The City Of New York Method for treatment of movement disorders
AU2006261893A1 (en) * 2005-06-23 2007-01-04 Combinatorx, Incorporated Improved dosage forms for movement disorder treatment
US20090176882A1 (en) * 2008-12-09 2009-07-09 Depomed, Inc. Gastric retentive gabapentin dosage forms and methods for using same
EP2101752A1 (en) * 2006-12-08 2009-09-23 Xenoport, Inc. Use of prodrugs of gaba analogs for treating diseases
WO2008115797A1 (en) * 2007-03-16 2008-09-25 Pavo, Inc. Therapeutic compositions and methods
MX360289B (es) * 2007-11-23 2018-10-29 Gruenenthal Gmbh Composiciones de tapentadol.
CA3066426A1 (en) * 2008-01-09 2009-07-16 Charleston Laboratories, Inc. Pharmaceutical compositions comprising an antiemetic and an opioid analgesic
US20110207718A1 (en) * 2008-08-06 2011-08-25 Gosforth Centre (Holdings) Pty Ltd. Compositions and methods for treating psychiatric disorders
US20100190752A1 (en) * 2008-09-05 2010-07-29 Gruenenthal Gmbh Pharmaceutical Combination
SI2331210T1 (sl) * 2008-09-05 2014-10-30 Gruenenthal Gmbh Farmacevtska kombinacija 3-(3-dimetilamino-1-etil-2-metil-propil)-fenola in antiepileptika
US20110268666A1 (en) * 2008-09-29 2011-11-03 Yissum Research Development Company of the Research University of Jerusalem, Ltd. Novel gastroretentive delivery system
AU2010221167B2 (en) * 2009-03-06 2014-04-03 Xenoport, Inc. Oral dosage forms having a high loading of a gabapentin prodrug
WO2011023392A1 (en) * 2009-08-28 2011-03-03 Grünenthal GmbH Pharmaceutical combination comprising 6-dimethylaminomethyl-1-(3-methoxy-phenyl)-cyclohexane-1,3-diol or 6-dimethylaminomethyl-1-(3-hydroxy-phenyl)-cyclohexane-1,3-diol and an antiepileptic

Similar Documents

Publication Publication Date Title
JP2005507400A5 (OSRAM)
JP2005508358A5 (OSRAM)
RU2011110765A (ru) Фармацевтическая композиция энтакапона или его солей пролонгрированного высвобождения
US20040131671A1 (en) Sustained release formulations containing acetaminophen and tramadol
CA2464322A1 (en) Methods of treatment using a gastric retained gabapentin dosage
CA2914365C (en) Acamprosate formulations, methods of using the same, and combinations comprising the same
JP2009102342A5 (OSRAM)
JP2007500154A5 (OSRAM)
RU2007126652A (ru) Композиции и способы стабилизации активных фармацевтических ингредиентов
WO2010103544A3 (en) A novel sustained release composition of compounds selected from the class of centrally acting muscle relaxants
JP2008543936A5 (OSRAM)
WO2007138466A2 (en) Pharmaceutical compositions comprising meloxicam and tramadol combination
TW200306799A (en) Combination of organic compounds
KR101156054B1 (ko) 안정한 에페리손 함유 서방성 의약조성물
RU2009110452A (ru) Галеновые составы алискирена
JPH059412B2 (OSRAM)
JP2005528430A5 (OSRAM)
JP2008519070A5 (OSRAM)
JP2019218379A5 (OSRAM)
JP5828609B2 (ja) 持続性解熱鎮痛消炎剤
TW200520748A (en) Modafinil modified release pharmaceutical compositions
DE60006362D1 (de) Kapseln mit loratadin und pseudoephedrin enthaltenden zusammensetzungen
BR112020003375A2 (pt) composições de amantadina, preparações das mesmas, e métodos de uso
TWI357329B (en) Pharmaceutical composition in the form of a gastri
WO2003084514A1 (en) Controlled release pharmaceutical compositions of carbidopa and levodopa